In the deal, the Cambridge, MA-based company will pay Adverum $1 million up front to evaluate its vectors for use in clinical development. It will also pay for all preclinical activity, partially via the upfront payment. Editas will pay another $1 million option exercise fee for each indication it chooses to pursue under the partnership. Adverum is eligible for other undisclosed development and commercial milestone payments and royalties. "Our innovative vectors have the potential to deliver Editas' genome editing components efficiently to the retina," said Adverum CEO Paul Cleveland. "This collaboration expands our opportunities to capitalize on our science, ophthalmology expertise and vector development know-how." In addition to LCA10, Editas also has programs in Duchenne muscular dystrophy and in hematopoietic stem/progenitor cells.